FirstIgnite is supporting the commercialization of Mississippi State University’s hexose phosphate conjugated drugs technology. This technology uses fluorinated hexose phosphate compounds to enhance the effectiveness of antibiotics. Additionally, these compounds improve the pharmacokinetics of antibiotics by enhancing antimicrobial transportation channels. Furthermore, fluorinated hexose phosphate compounds can be utilized as carrier molecules for existing antimicrobial agents that were retired due to low pharmacokinetics and resistance.
This invention has the potential to effectively treat ESKAPE pathogens, which are known to be multidrug-resistant and include Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species. These pathogens are responsible for causing an estimated $20 billion dollars in excess healthcare costs in the US.
Mississippi State University’s hexose phosphate conjugated drugs technology is ready for collaboration (licensing, partnerships, industry feedback, etc.). Is your company the right fit? If you’d be available for a conversation with the Mississippi State University team, you can schedule a time directly on their team’s calendar here.